振德医疗
(603301)
| 流通市值：208.41亿 | | | 总市值：208.41亿 |
| 流通股本：2.64亿 | | | 总股本：2.64亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,224,060,634.54 | 1,000,414,155.6 | 4,329,600,957.47 | 3,184,260,011.92 |
| 营业收入 | 2,224,060,634.54 | 1,000,414,155.6 | 4,329,600,957.47 | 3,184,260,011.92 |
| 二、营业总成本 | 2,067,911,454.1 | 946,996,184.26 | 4,007,579,350.63 | 2,957,601,989.7 |
| 营业成本 | 1,454,743,382.89 | 654,526,645.96 | 2,860,975,486.02 | 2,103,773,741.39 |
| 税金及附加 | 27,522,881.31 | 13,480,879.39 | 53,528,474.28 | 39,807,783.22 |
| 销售费用 | 185,477,351.18 | 92,983,220.89 | 362,792,725.12 | 263,603,578.84 |
| 管理费用 | 304,963,031.93 | 139,918,521.52 | 563,203,958.76 | 424,806,793.26 |
| 研发费用 | 64,888,620.92 | 30,608,135.3 | 142,430,708.47 | 99,515,975.55 |
| 财务费用 | 30,316,185.87 | 15,478,781.2 | 24,647,997.98 | 26,094,117.44 |
| 其中:利息费用 | 15,709,188.11 | 8,132,416.14 | 31,487,485.79 | 25,032,931.45 |
| 其中:利息收入 | 2,539,094.22 | 1,366,300.51 | 15,534,412.82 | 10,497,300.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,690,009.7 | 11,530,488.74 | 634,530.76 | 2,715,586.97 |
| 加:投资收益 | 22,946,175.57 | 2,705,538.1 | 10,458,035.19 | 8,488,498.77 |
| 资产处置收益 | -8,313,935.18 | -381,801.07 | 637,358.48 | 921,169.55 |
| 资产减值损失(新) | -21,588,938.29 | -9,507,952.19 | -33,929,277 | -13,174,456.72 |
| 信用减值损失(新) | -2,834,702.62 | 1,173,168.67 | -13,107,055.97 | -5,361,175.31 |
| 其他收益 | 18,318,613.35 | 8,268,266.05 | 41,629,927.91 | 29,476,191.39 |
| 四、营业利润 | 175,366,402.97 | 67,205,679.64 | 328,345,126.21 | 249,723,836.87 |
| 加:营业外收入 | 75,216.88 | 4,428.8 | 1,556,735.7 | 674,073.13 |
| 减:营业外支出 | 2,743,707.78 | 1,578,763.7 | 5,072,275.47 | 1,569,002.4 |
| 五、利润总额 | 172,697,912.07 | 65,631,344.74 | 324,829,586.44 | 248,828,907.6 |
| 减:所得税费用 | 21,647,160.54 | 8,071,361.04 | 57,727,770.86 | 38,285,135.52 |
| 六、净利润 | 151,050,751.53 | 57,559,983.7 | 267,101,815.58 | 210,543,772.08 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 151,050,751.53 | 57,559,983.7 | 267,101,815.58 | 210,543,772.08 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 143,778,780.32 | 54,448,031.38 | 260,817,281.43 | 203,186,185.96 |
| 少数股东损益 | 7,271,971.21 | 3,111,952.32 | 6,284,534.15 | 7,357,586.12 |
| 扣除非经常损益后的净利润 | 119,050,538.29 | 43,183,996.15 | 240,311,425.95 | 182,817,829.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.54 | 0.2 | 0.99 | 0.76 |
| (二)稀释每股收益 | 0.54 | 0.2 | 0.99 | 0.76 |
| 八、其他综合收益 | -57,189,920.69 | -24,472,243.1 | -4,740,185.93 | 43,702,079.94 |
| 归属于母公司股东的其他综合收益 | -46,354,738.06 | -16,218,838.1 | -12,087,291.03 | 29,645,996.27 |
| 九、综合收益总额 | 93,860,830.84 | 33,087,740.6 | 262,361,629.65 | 254,245,852.02 |
| 归属于母公司股东的综合收益总额 | 97,424,042.26 | 38,229,193.28 | 248,729,990.4 | 232,832,182.23 |
| 归属于少数股东的综合收益总额 | -3,563,211.42 | -5,141,452.68 | 13,631,639.25 | 21,413,669.79 |
| 公告日期 | 2026-08-28 | 2026-04-24 | 2026-04-24 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |